卡培他滨单药一线治疗Ⅱa期老年乳腺癌的临床研究  

Clinical observation of capecitabine as first-line monotherapy in elderly patients with Ⅱa breast cancer

作　　者：胡薇[1] 施俊义[1] 盛援[1] 李莉[1] 

机构地区：[1]第二军医大学长海医院甲乳外科,上海200433

出　　处：《第二军医大学学报》2009年第2期187-189,共3页Academic Journal of Second Military Medical University

摘　　要：目的:观察卡培他滨单药一线治疗Ⅱa期老年乳腺癌的临床疗效和不良反应。方法:2002年6月至2005年6月本院收治的71例Ⅱa期老年乳腺癌,患者术后分别行卡培他滨单药口服化疗(X组)及CEF方案化疗(CEF组)。结果:X组3年和5年总生存率分别为97.06%、94.12%,复发及转移率为5.88%,均与CEF组患者无明显差异(P>0.05)。X组具有口服给药的优势,不良反应以手足综合征为主,发生率82.35%,均可耐受,其胃肠道反应以及骨髓抑制程度等均显著低于CEF组(P<0.01),未有因不良反应减量、中断或放弃化疗者,且无明显化疗恐惧感。结论:对于Ⅱa期老年乳腺癌患者术后采用卡培他滨单药口服化疗疗效可靠,给药方便,不良反应极小,患者对治疗的耐受及依从性佳。Objective：To observe the clinical effect and adverse reaction of capecitabine as first-line monotherapy in elderly patients with stage Ⅱ a breast cancer. Methods： From June 2002 to June 2005,71 elderly patients with stage Ⅱ a breast cancer received chemotherapy （different scheme： capecitabine group and CEF group） after operation. The efficacies and adverse reactions were evaluated and compared between the two groups. Results： The 3-year and 5-year survival rates of patients in capecitabine group were 97. 06% and 94.12% ,respectively; the relapse rate was 5.88% ; all were comparable to those of CEF group. One of the advantages of capecitabine was its oral administration. The adverse effect of capecitabine was mainly hand- foot syndrome,with an incidence of 82. 35%, but was tolerable. The gastrointestinal reaction and bone marrow repression in capecitabine group were significantly lower than those in the CEF group（P〈0.01）. There was no giving up of treatment due to adverse reactions or fear of chemotherapy in our group. Conelusion： Capecitabine is effective and safe in the treatment of elderly patients with stage Ⅱ a breast cancer; it is easy to take,with less adverse effects and better patient compliance.

关 键 词：乳腺肿瘤 药物疗法 卡培他滨 老年人 

分 类 号：R737.9[医药卫生—肿瘤]